NASDAQ:CBAY - CymaBay Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.93 -0.22 (-2.40 %)
(As of 01/22/2019 03:10 AM ET)
Previous Close$9.15
Today's Range$8.84 - $9.20
52-Week Range$6.31 - $15.59
Volume345,113 shs
Average Volume369,788 shs
Market Capitalization$530.79 million
P/E Ratio-11.30
Dividend YieldN/A
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CBAY



Sales & Book Value

Annual Sales$10 million
Book Value$1.53 per share


Net Income$-27,550,000.00


Market Cap$530.79 million

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) announced its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.04. View CymaBay Therapeutics' Earnings History.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for CymaBay Therapeutics.

What price target have analysts set for CBAY?

9 brokers have issued 1 year target prices for CymaBay Therapeutics' shares. Their forecasts range from $17.00 to $30.00. On average, they anticipate CymaBay Therapeutics' stock price to reach $21.75 in the next twelve months. This suggests a possible upside of 143.6% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.

What is the consensus analysts' recommendation for CymaBay Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CymaBay Therapeutics.

What are Wall Street analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
  • 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (1/21/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate the Overweight rating and 12-month PT of $16 for CBAY stock. We believe evidence provided thus far support the notion that seladelpar will become an important new agent for treating primary biliary cholangitis (PBC) by virtue of its potentially superior safety profile characterized by the lack of pruritus induction. Efficacy as a treatment for non-alcoholic steatohepatitis (NASH) would significantly increase the drug’s commercial potential and broaden interest in the company from other biopharma industry participants, in our view." (8/9/2018)
  • 3. HC Wainwright analysts commented, "EASL; Phase 3 Initiation in 2H18 on Track; Affirm Buy Stock Data 03/27/2018 Price $12.00 Exchange NASDAQ Price Target $18.00 52-Week High $15.59 52-Week Low $3.16 Enterprise Value (M) $611.7 Market Cap (M) $702 Public Market Float (M) 19.5 Shares Outstanding (M) 58.5 3 Month Avg Volume 980,454 Short Interest (M) 2.59 Balance Sheet Metrics Cash (M) $97.2 Total Debt (M) $6.9 Total Cash/Share $1.66 Book Value/Share $2.16 Cash (M): Amount shown is as of December 31 and does not include the $135.5M net proceeds from the recent equity raise.. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.29) (0.20) (0.21) 2Q (0.30) (0.31) (0.22) 3Q (0.25) (0.21) (0.25) 4Q (0.30) (0.11) (0.27) FY (1.14) (0.79) (0.95) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.0 4.8 0.0 2Q 0.0 0.0 0.0 3Q 0.0 0.0 0.0 4Q 0.0 5.2 0.0 FY 0.0 10.0 5.0 20 15 10 5 0 MAR- 17 J UL- 17 NOV- 17 MAR- 18 12 10 8 6 4 2 0 Vol." (3/28/2018)

Has CymaBay Therapeutics been receiving favorable news coverage?

News stories about CBAY stock have been trending very positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CymaBay Therapeutics earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)
  • Dr. Pol F. Boudes, Chief Medical Officer (Age 62)
  • Mr. Daniel Menold, VP of Fin. (Age 49)
  • Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $8.93.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $530.79 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-27,550,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. CymaBay Therapeutics employs 26 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7999 GATEWAY BLVD SUITE 130, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]

MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  522
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel